October 21 2022
Day Zero receives $8.2M from CARB-X to speed development of infectious disease diagnostics.
October 20 2022
Additional CARB-X funding supports the transition into product development of the firm's whole-genome sequencing and machine learning-based approach to antimicrobial resistance profiling.
January 5 2022
Learn how we are predicting antimicrobial susceptibility directly from blood using whole-genome sequencing with Day Zero Diagnostic's Scientific Co-founder, Melis Anahtar, MD, Phd.
January 4 2022
Day Zero Diagnostics was featured in AACC's December issue of "Clinical Laboratory News", highlighting our work around whole genome sequencing and machine learning for rapid diagnosis of infections directly from blood.
September 29 2021
Day Zero is proud to have been selected for the Disruptive Technology Award from AACC
December 16 2020
Day Zero is honored to be included in this group of innovative companies disrupting traditional lab testing